Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Azelis will strengthen its presence in the domestic market by leveraging portfolio synergies, actively consolidating the business, and creating value for all stakeholders
The FDA set a target action date of April 28, 2026, under the Prescription Drug User Fee Act
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
Subscribe To Our Newsletter & Stay Updated